These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 38664592)

  • 1. Post-translational modifications in kidney diseases and associated cardiovascular risk.
    Noels H; Jankowski V; Schunk SJ; Vanholder R; Kalim S; Jankowski J
    Nat Rev Nephrol; 2024 Aug; 20(8):495-512. PubMed ID: 38664592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Avenues for post-translational protein modification prevention and therapy.
    Tang M; Kalim S
    Mol Aspects Med; 2022 Aug; 86():101083. PubMed ID: 35227517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging role of post-translational modifications in chronic kidney disease and cardiovascular disease.
    Gajjala PR; Fliser D; Speer T; Jankowski V; Jankowski J
    Nephrol Dial Transplant; 2015 Nov; 30(11):1814-24. PubMed ID: 25862763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Role of protein carbamylation in chronic kidney disease complications].
    Gillery P; Jaisson S; Gorisse L; Pietrement C
    Nephrol Ther; 2015 Jun; 11(3):129-34. PubMed ID: 25794932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guanidinylations of albumin decreased binding capacity of hydrophobic metabolites.
    Rueth M; Lemke HD; Preisinger C; Krieter D; Theelen W; Gajjala P; Devine E; Zidek W; Jankowski J; Jankowski V
    Acta Physiol (Oxf); 2015 Sep; 215(1):13-23. PubMed ID: 25939450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative study of extrapolative factors linked with oxidative injury and anti-inflammatory status in chronic kidney disease patients experiencing cardiovascular distress.
    Rasool M; Ashraf MA; Malik A; Waquar S; Khan SA; Qazi MH; Ahmad W; Asif M; Khan SU; Zaheer A; Qaisrani MM; Khan AR; Iqbal A; Raza A; Iram S; Kamran K; Iqbal A; Mustafa MZ; Choudhry H; Zamzami MA; Abdulaal WH; Jamal MS
    PLoS One; 2017; 12(2):e0171561. PubMed ID: 28178330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carbamylated Proteins in Renal Disease: Aggravating Factors or Just Biomarkers?
    Gorisse L; Jaisson S; Piétrement C; Gillery P
    Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations.
    Noels H; Lehrke M; Vanholder R; Jankowski J
    Nat Rev Nephrol; 2021 Aug; 17(8):528-542. PubMed ID: 33972752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uremic Toxicity of Advanced Glycation End Products in CKD.
    Stinghen AE; Massy ZA; Vlassara H; Striker GE; Boullier A
    J Am Soc Nephrol; 2016 Feb; 27(2):354-70. PubMed ID: 26311460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Nonenzymatic Post-translational Protein Modifications in Uremic Vascular Calcification.
    Lim K; Kalim S
    Adv Chronic Kidney Dis; 2019 Nov; 26(6):427-436. PubMed ID: 31831121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal insufficiency and chronic kidney disease - Promotor or consequence of pathological post-translational modifications.
    Laget J; Duranton F; Argilés À; Gayrard N
    Mol Aspects Med; 2022 Aug; 86():101082. PubMed ID: 35153062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Uremic Toxins on Endothelial Dysfunction in Chronic Kidney Disease: A Systematic Review.
    Harlacher E; Wollenhaupt J; Baaten CCFMJ; Noels H
    Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipoproteins in chronic kidney disease: from bench to bedside.
    Speer T; Ridker PM; von Eckardstein A; Schunk SJ; Fliser D
    Eur Heart J; 2021 Jun; 42(22):2170-2185. PubMed ID: 33393990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uraemic solutes as therapeutic targets in CKD-associated cardiovascular disease.
    Ravid JD; Kamel MH; Chitalia VC
    Nat Rev Nephrol; 2021 Jun; 17(6):402-416. PubMed ID: 33758363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Histone Modifications in Kidney Fibrosis.
    Pan S; Yuan T; Xia Y; Yu W; Zhou X; Cheng F
    Medicina (Kaunas); 2024 May; 60(6):. PubMed ID: 38929505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of oxidative stress on chronic kidney disease progression.
    Putri AY; Thaha M
    Acta Med Indones; 2014 Jul; 46(3):244-52. PubMed ID: 25348188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. S100/Calgranulin-mediated inflammation accelerates left ventricular hypertrophy and aortic valve sclerosis in chronic kidney disease in a receptor for advanced glycation end products-dependent manner.
    Yan L; Mathew L; Chellan B; Gardner B; Earley J; Puri TS; Hofmann Bowman MA
    Arterioscler Thromb Vasc Biol; 2014 Jul; 34(7):1399-411. PubMed ID: 24855059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irreversible post-translational modifications - Emerging cardiovascular risk factors.
    Wu Z; Jankowski V; Jankowski J
    Mol Aspects Med; 2022 Aug; 86():101010. PubMed ID: 34404548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carbamylated sortilin associates with cardiovascular calcification in patients with chronic kidney disease.
    Jankowski V; Saritas T; Kjolby M; Hermann J; Speer T; Himmelsbach A; Mahr K; Heuschkel MA; Schunk SJ; Thirup S; Winther S; Bottcher M; Nyegard M; Nykjaer A; Kramann R; Kaesler N; Jankowski J; Floege J; Marx N; Goettsch C
    Kidney Int; 2022 Mar; 101(3):574-584. PubMed ID: 34767831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The axis AGE-RAGE-soluble RAGE and oxidative stress in chronic kidney disease.
    Gugliucci A; Menini T
    Adv Exp Med Biol; 2014; 824():191-208. PubMed ID: 25039001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.